Terms: = Lung cancer AND BTG1, P62324, 694, ENSG00000133639 AND Diagnosis
27 results:
1. Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions.
Zhou J; Wen Y; Ding R; Liu J; Fang H; Li X; Zhao K; Wan Q
Cancer Imaging; 2024 Jan; 24(1):14. PubMed ID: 38246984
[TBL] [Abstract] [Full Text] [Related]
2. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
Oh BC; Cho AR; Nam JH; Yang SY; Kim MJ; Kwon SH; Lee EK
BMC Cancer; 2023 May; 23(1):482. PubMed ID: 37248452
[TBL] [Abstract] [Full Text] [Related]
3. Serum Metabolomic Profiles for Distinguishing lung cancer From Pulmonary Tuberculosis: Identification of Rapid and Noninvasive Biomarker.
Chen S; Li C; Qin Z; Song L; Zhang S; Sun C; Zhuang P; Wang Y; Yang B; Ning L; Li Y
J Infect Dis; 2023 Nov; 228(9):1154-1165. PubMed ID: 37246562
[TBL] [Abstract] [Full Text] [Related]
4. Immunotherapy with Autoimmune Complication in Renal cancer.
Sunil SP; Kumar S; Hussaini S; Kandula S
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116021
[TBL] [Abstract] [Full Text] [Related]
5. Routine practice data of three cancer entities: Comparison among cancer registry and health insurance data.
Lang LM; Behr C; Ludwig M; Walker J; Christian Lange H; Basedow F; Justenhoven C
Z Evid Fortbild Qual Gesundhwes; 2023 Apr; 177():65-72. PubMed ID: 36804770
[TBL] [Abstract] [Full Text] [Related]
6. diagnosis of Benign and Malignant Pulmonary Ground-Glass Nodules Using Computed Tomography Radiomics Parameters.
Liang L; Zhang H; Lei H; Zhou H; Wu Y; Shen J
Technol Cancer Res Treat; 2022; 21():15330338221119748. PubMed ID: 36259167
[No Abstract] [Full Text] [Related]
7. Risk assessment of malignancy in solitary pulmonary nodules in lung computed tomography: a multivariable predictive model study.
Liu HY; Zhao XR; Chi M; Cheng XS; Wang ZQ; Xu ZW; Li YL; Yang R; Wu YJ; Zhang XJ
Chin Med J (Engl); 2021 Jun; 134(14):1687-1694. PubMed ID: 34397595
[TBL] [Abstract] [Full Text] [Related]
8. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract] [Full Text] [Related]
10. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
Sargen MR; Cahoon EK; Lynch CF; Tucker MA; Goldstein AM; Engels EA
JAMA Dermatol; 2020 Dec; 156(12):1307-1314. PubMed ID: 33146669
[TBL] [Abstract] [Full Text] [Related]
11. Patient-level factors associated with chronic opioid use in cancer: a population-based cohort study.
Cuthbert CA; Xu Y; Kong S; Boyne DJ; Hemmelgarn BR; Cheung WY
Support Care Cancer; 2020 Sep; 28(9):4201-4209. PubMed ID: 31900614
[TBL] [Abstract] [Full Text] [Related]
12. Energy spectrum computed tomography improves the differentiation between benign and malignant solitary pulmonary nodules.
Zhao J; Chai Y; Zhou J; Zhang Z; Wang Z
Clin Invest Med; 2019 Sep; 42(3):E40-E46. PubMed ID: 31563159
[TBL] [Abstract] [Full Text] [Related]
13. Non-melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population-based cohort study.
Yun SJ; Bae JM; Kim H; Park BC; Kim JS; Seo SH; Ahn HH; Lee DY; Kim YC; Park HJ; Chung KY
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):746-753. PubMed ID: 31494979
[TBL] [Abstract] [Full Text] [Related]
14. circMAN1A2 could serve as a novel serum biomarker for malignant tumors.
Fan CM; Wang JP; Tang YY; Zhao J; He SY; Xiong F; Guo C; Xiang B; Zhou M; Li XL; Li Y; Li GY; Xiong W; Zeng ZY
Cancer Sci; 2019 Jul; 110(7):2180-2188. PubMed ID: 31046163
[TBL] [Abstract] [Full Text] [Related]
15. Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers.
Bai Y; Qiao L; Xie N; Shi Y; Liu N; Wang J
PLoS One; 2017; 12(9):e0184902. PubMed ID: 28922388
[TBL] [Abstract] [Full Text] [Related]
16. Smoking-associated DNA methylation markers predict lung cancer incidence.
Zhang Y; Elgizouli M; Schöttker B; Holleczek B; Nieters A; Brenner H
Clin Epigenetics; 2016; 8():127. PubMed ID: 27924164
[TBL] [Abstract] [Full Text] [Related]
17. Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer.
Barry KH; Moore LE; Liao LM; Huang WY; Andreotti G; Poulin M; Berndt SI
Prostate; 2015 Nov; 75(15):1718-25. PubMed ID: 26250474
[TBL] [Abstract] [Full Text] [Related]
18. Overestimated value of (18)F-FDG PET/CT to diagnose pulmonary nodules: Analysis of 298 patients.
Li S; Zhao B; Wang X; Yu J; Yan S; Lv C; Yang Y
Clin Radiol; 2014 Aug; 69(8):e352-7. PubMed ID: 24877581
[TBL] [Abstract] [Full Text] [Related]
19. Increased risk of cancer among gout patients: a nationwide population study.
Kuo CF; Luo SF; See LC; Chou IJ; Fang YF; Yu KH
Joint Bone Spine; 2012 Jul; 79(4):375-8. PubMed ID: 22088929
[TBL] [Abstract] [Full Text] [Related]
20. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract] [Full Text] [Related]
[Next]
